Regimens to treat multidrug-resistant tuberculosis: past, present and future perspectives

Global TB Network Clinical Trials, Emanuele Pontali, Mario C. Raviglione, Giovanni Battista Migliori*

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review

31 Citations (Scopus)
99 Downloads (Pure)


Over the past few decades, treatment of multidrug-resistant (MDR)/ extensively drugresistant (XDR) tuberculosis (TB) has been challenging because of its prolonged duration (up to 2024 months), toxicity, costs and sub-optimal outcomes. After over 40 years of neglect, two new drugs (bedaquiline and delamanid) have been made available to manage difficult-to-treat MDR-/XDR-TB cases. World Health Organization (WHO) guidelines published in March 2019 endorsed the possibility of treating MDR-TB patients with a full oral regimen, following previous guidelines published in 2016 which launched a shorter regimen lasting 9-10 months.

The objectives of this article are to review the main achievements in MDR-TB treatment through the description of the existing WHO strategies, to discuss the main ongoing trials and to shed light on potential future scenarios and revised definitions necessary to manage drug-resistant TB.

Original languageEnglish
Article number190035
Number of pages7
JournalEuropean Respiratory Review
Issue number152
Publication statusPublished - 30-Jun-2019


  • TB

Cite this